Before Inha Univ.

 

38.  Photothermal therapy combined with neoantigen cancer vaccination for effective immunotherapy

against large established tumors and distant metastasis.

Nam J*, Son S*, Park K, Moon J. J.

Advanced Therapeutics (2021), 2100093. (IF=4.6, Top 25.40%)​

​

37.  Personalized combination nano-immunotherapy for robust induction and tumor infiltration of

CD8+ T cells.

Park K, Nam J, Son S, Moon J. J.

Biomaterials (2021), 274, 120844. (IF=14, Top 1.32%)​

​

36.  Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and

SARS-CoV-2.

Park K, Bazzill J, Son S, Nam J, Shin SW, Stuckey J, Meagher J, Song J, Montefiori DC, LaBranche CC, Smith J, Xu J, and Moon J. J.

Journal of Controlled Release (2021), 330, 529-539. (IF=10.8, Top 3.51%)​

​

35.  Modularly programmable nanoparticle vaccine based on polyethyleneimine for personalized c

cancer immunotherapy.

Nam J*, Son S*, Park K, Moon J. J.

Advanced Science (2021), 8 (5), 2002577. (IF=15.1, Top 4.94%)​

2021

​​

​

34.  Synthetic high-density lipoprotein nanodiscs for personalized immunotherapy against gliomas.

Scheetz L, Kadiyala P, Sun X, Son S, Najafabadi A, Aikins M, Lowenstein P, Schwendeman A, Castro M, and Moon J. J.

Clinical Cancer Research (2020), 26, 16, 4369-4380. (IF=11.5, Top 8.90%)​

​

33.  Sugar-Nanocapsules imprinted with Microbial Molecular Patterns for mRNA Vaccination.

Son S*, Nam J*, Zenkov I, Ochyl LJ, Xu Y, Scheetz L, Shi J, Farokhzad O. C.# Moon J. J.#

Nano Letters (2020), 20, 3, 1499-1509. (IF=10.8, Top 5.74%)​

2020

​​

​

32.  Cancer nanomedicine for combination cancer immunotherapy.

Nam J*, Son S*, Park K, Zou W, Shea L. D., Moon J. J.#

Nature Review Materials (2019), 4 (6), 398-414. (IF=83.5, Top 0.18%)​

2019

​​

​

31.  Elimination of established tumors with nanodisc-based combination chemoimmunotherapy.

Kuai R*, Yuan W*, Son S, Nam J, Xu Y, Fan Y, Schwendeman A, and Moon J. J.

Science Advances (2018), 4, eaao1736. (IF=13.6, Top 5.07%)​

​

30.  Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced

metastatic cancer.

Nam J*, Son S*, Ochyl LJ, Kuai R, Schwendeman A, Moon J. J.

Nature Communication (2018), 9, 1074. (IF=16.6, Top 3.91%)​

2018

​​

​

29.  Deep tissue penetration of nanoparticles using pulsed-high intensity focused ultrasound.

You DG, Yoon HY, Jeon S, Um W, Son S, Park JH, Kwon IC, Kim K.

Nano convergence (2017), 4, 30. (IF=11.7, Top 7.20%)​

​

28.   Adjuvant-loaded spiky gold nanoparticles for activation of innate immune  cells.

Nam J, Son S, Moon J. J.

Cellular and molecular bioengineering (2017), 10, 341-355. (IF=2.8, Top 71.53%)​

​

27.   Antitumor therapeutic application of self-assembled RNAi-AuNP nanoconstructs: Combination of

VEGF-RNAi and photothermal ablation.

Son S*, Kim N*, You DG, Yoon HY, Yhee JY, Kim K, Kwon IC, Kim SH.

Theranostics (2017), 7, 9. (IF=12.4, Top 6.85%)​

2017

​​

​

26.  Chemical gas-generating nanoparticles for tumor-targeted ultrasound imaging and ultrasound-

triggered drug delivery.

Min HS*, Son S*, You DG, Lee TW, Lee S, Lee J, Han MH, Park JH, Kim SH, Choi K, Park K, Kim,  K, Kwon IC.

Biomaterials (2016), 108, 57. (IF=14, Top 1.52%)​

​

25.  Reducible polyethylenimine nanoparticles for efficient siRNA delivery in corneal

neovascularization therapy.

Han H*, Son S*, Son S, Kim N, Yhee JY, Lee JH, Choi JS, Joo CK, Lee H, Kim WJ, Kim SH, Kwon, IC, Kim H, Kim K.

Macromolecular Bioscience (2016), 16, 11, 1583, Highlighted in Cover Picture. (IF=4.6, Top 12.80%)​

​

24.  ROS-generating TiO2 nanoparticles for non-invasive sonodynamic therapy of cancer.

You DG, Deepagan VG, Um W, Jeon S, Son S, Chang H, Yoon HI, Cho YW, Swierczewska M, Lee S, Pomper MG, Kwon IC, Kim K, Park JH.

Scientific Reports (2016), 6, 23200. (IF=4.6, Top 7.89%)​

2016

​​

​

23.  Echogenic glycol chitosan nanoparticles for ultrasound-triggered cancer theranostics.

Min HS, You DG, Son S, Jeon S, Yhee J, Park JH, Lee S, Kwon IC, Kim K.

Theranostics. Highlighted in Cover Picture (2015), 5, 12, 1402-1418. (IF=12.4, Top 6.85%)​

​

22.  Nanoparticle-based combination therapy for cancer treatment.

Yhee JY, Son S, Lee H, Kim K.

Current Pharmaceutical Design (2015), 21, 22, 3158-66. (IF=3.1, Top 24.41%)​

2015

​​

​

21.  Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to

overcome drug resistance.

Yhee JY, Song S, Lee SJ, Park S, Kim K, Kim MG, Son S, Koo H, Kwon IC, Jeong JH, Jeong SY, Kim SH,

Kim K.

Journal of Controlled Release (2014), 198, 28, 1-9. (IF=10.8, Top 3.64%)​

​

20.  Glycol chitosan nanoparticles as highly specialized cancer therapeutic vehicles: Sequential

delivery of doxorubicin and Bcl-2 siRNA.

Yoon HY*, Son S*, Lee SJ, You DG, Yhee JY, Park JH, Swierczewska M, Lee S, Kwon IC, Kim SH, Kim K, Promper Scientific Reports (2014), 4, 6878. (IF=4.6, Top 13.39%)​

​

19.  Echogenic nanoparticles for ultrasound technologies; evolution from diagnostic imaging modality

to multimodal theranostic agent.

Son S*, Min HS*, You DG, Kim BS, Kwon IC.

Nano Today (2014), 9, 4, 525-540. (IF=17.4, Top 1.45%)​

​

18.  i-motif-driven Au nanomachines in programmed siRNA delivery for gene-silencing and

photothermal ablation.

Son S*, Nam J*, Kim J, Kim S, Kim WJ.

ACS Nano (2014), 8, 6, 5574-5584. (IF=17.1, Top 3.14%)​

2014

​​

​

17.  Tumor-targeting Transferrin Nanoparticles for Systemic Polymerized siRNA Delivery in Tumor-

bearing Mice.

Yhee JY, Lee SJ, Lee S, Song S, Min HS, Kang, SW, Son S, Jeong SY, Kim SH, Kim K.

Bioconjugate Chemistry (2013), 24, 11, 1850-1860. (IF=4.7, Top 13.39%)​

​

16.  Liver-specific and echogenic hyaluronic acid nanoparticles facilitating liver cancer discrimination.

Min HS*, Son S*, Lee TW, Koo, H, Yoon HY, Na JH, Choi Y, Park JH, Lee J, Han M, Park RW, Kim IS, Jeong SY, Kim SH, Kwon IC, Kim K.

Advanced Functional Materials (2013), 23, 44, 5518-5529. (IF=19, Top 4.09%)​

Highlighted in Cover Picture.

​

15.  Structural modification of siRNA for efficient gene silencing.

Lee SJ*, Son S*; Yhee JY, Choi K, Kwon IC, Kim SH, Kim K.

Biotechnology Advances (2013), 31, 5, 491-503. (IF=16, Top 2.22%)​

2013

​​

​

14.  A Review of RGD-functionalize non-viral gene delivery vectors for cancer therapy.

Park J, Singha K, Son S, Kim J, Namgung R, Yun CO, Kim WJ.

Cancer Gene Therapy (2012), 19, 741-748. (IF=6.4, Top 20.31%)​

​

13.  Bioreducible polymers for gene silencing and delivery.

Son S*, Namgung R, Kim J, Singha K, Kim WJ.

Account of Chemical Research (2012), 45, 1100-1112. (IF=18.3, Top 1.70%)​

​

12.  Sustained cytoplasmic delivery and anti-viral effect of PLGA nanoparticles carrying a nucleic acid-

hydrolyzing monoclonal antibody.

Joung YK*, Son S*, Jang JY, Kwon MH, Park KD.

Pharmaceutical Research (2012), 29, 932-942. (IF=3.7, Top 12.90%)​

2012

​​

​

11.  Artificial Cell Membrane-mimicking Nanostructure Facilitates Efficient Gene Delivery through

Fusogenic Interaction with the Plasma Membrane of Living Cells.

Son S*, Kim G, Singha K, Park S, Ree M, Kim WJ.

Small (2011), 7, 2991-2997, Highlighted  in the frontispiece. (IF=13.3, Top 5.84%)​

​

10.  Biodegradable Particulate Delivery of Vascular Endothelial Growth Factor Plasmid from 

Polycaprolactone/Polyethylenimine Electrospun Nanofibers for the Treatment of Myocardial Infarction.

Che HL, Muthiah M, Ahn Y, Son S, Kim WJ, Seonwoo H, Chung JH, Cho CS, Park IK.

Journal of Nanoscience and Nanotechnology (2011), 11, 1-5. (IF=1.134, Top 39.95%)​

​

9.    A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of

neurogenic microRNA.

Hwang DW, Son S, Jang J, Youn H, Lee S, Lee D, Lee YS, Jeong JM, Kim WJ, Lee DS.

Biomaterials (2011), 32, 4968-4975. (IF=14, Top 2.00%)​

​

8.    Matrix metalloproteinase-sensitive thermogelling polymer for bioresponsive local drug delivery.

Garripelli VK, Kim JK, Son S, Kim WJ, Repka MA, Jo S.

Acta Biomaterialia (2011), 7, 1984-1992. (IF=9.7, Top 4.24%)​

​

7.    RVG peptide tethered bioreducible polyethylenimine for gene delivery to brain.

Son S*, Hwang DW, Singha K, Jeong JH, Park TG, Lee DS, Kim WJ.

Journal of Controlled Release (2011), 155, 18-25. (IF=10.8, Top 5.70%)​

​

6.    DNA-functionalized nanochannels for SNP detection.

Yang SY*, Son S*, Jang S, Kim H, Jeon G, Kim WJ, Kim JK.

Nano Letters (2011), 11, 1032-1035. (IF=10.8, Top 3.04%)​

​

5.    Bioreducible BPEI-SS-PEG-cNGR polymer as a tumor targeted nonviral gene carrier.

Son S*, Singha K, Kim WJ.

Biomaterials (2011), 31, 6344-6354. (IF=14.0, Top 2.00%)​​

2011

​​

​

4.    The biocompatibility of self-assembled brush polymers bearing glycine derivatives.

Kim G, Rho Y, Park S, Kim H, Son S, Kim H, Kim IJ, Kim JR, Kim WJ, Ree M.

Biomaterials (2010), 31, 3816-3826. (IF=14.0, Top 2.50%)​

​

3.    Biodegradable nanoparticles modified by branched polyethylenimine for plasmid DNA delivery.

Son S*, Kim WJ.

Biomaterials (2010), 31, 133-143. (IF=14.0, Top 2.50%)​

2010

​​

​

​2.    An acid-labile temperature-responsive sol-gel reversible polymer for enhanced gene delivery to the

myocardium and skeletal muscle cells.

Namgung R, Nam S, Kim SK, Son S, Singha K, Kwon JS, Ahn Y, Jeong MH, Park IK, Garripelli VK, Jo S,

Kim WJ.​

Biomaterials (2009), 30, 5225-5233. (IF=14.0, Top 3.12%)​

​

1.    Optimized stability retention of a monoclonal antibody in the PLGA nanoparticles.

Son S*, Lee WR, Joung YK, Kwon MH, Kim YS, Park KD.
International Journal of Pharmaceutics (2009), 368,178-185. (IF=5.8, Top 38.29%)​

2009​